MKNK1 and breast carcinoma: Expanding upon our previous studies with our lead Mnk1/2 protein degrader VNLG-152R, in a variety of breast cancer subtypes, in vitro [39], we focused on studying the impact of VNLG-152R and its two pure enantiomers, specifically in several in vitro human triple negative breast cancer (TNBC) subtypes and in vivo xenograft and metastasis models of TNBC.